|
AR044519A1
(es)
|
2003-05-02 |
2005-09-14 |
Novartis Ag |
Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
|
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
EP2532677A1
(en)
|
2005-10-21 |
2012-12-12 |
Novartis AG |
Human antibodies against il13 and therapeutic uses
|
|
GB0526244D0
(en)
|
2005-12-22 |
2006-02-01 |
Novartis Ag |
Organic compounds
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
HRP20120494T1
(hr)
|
2006-04-21 |
2012-08-31 |
Novartis Ag |
Derivati purina za uporabu kao agonista adenozin a2a receptora
|
|
JP2010504933A
(ja)
|
2006-09-29 |
2010-02-18 |
ノバルティス アーゲー |
Pi3k脂質キナーゼ阻害剤としてのピラゾロピリミジン
|
|
BRPI0718266A2
(pt)
|
2006-10-30 |
2014-01-07 |
Novartis Ag |
Compostos heterocíclicos como agentes anti-inflamatórios.
|
|
US7978848B2
(en)
*
|
2007-01-09 |
2011-07-12 |
Microsoft Corporation |
Content encryption schema for integrating digital rights management with encrypted multicast
|
|
AU2007342223B2
(en)
|
2007-01-10 |
2011-02-24 |
Irm Llc |
Compounds and compositions as channel activating protease inhibitors
|
|
EP2332933A1
(en)
|
2007-05-07 |
2011-06-15 |
Novartis AG |
Epithelial sodium channel (ENaC) inhibitors
|
|
WO2009061516A1
(en)
*
|
2007-11-08 |
2009-05-14 |
New York University School Of Medicine |
Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening
|
|
BRPI0820669A2
(pt)
|
2007-12-10 |
2020-08-04 |
Novartis Ag |
compostos orgânicos
|
|
JP5584138B2
(ja)
|
2008-01-11 |
2014-09-03 |
ノバルティス アーゲー |
キナーゼ阻害剤としてのピリミジン類
|
|
KR20110040818A
(ko)
|
2008-06-10 |
2011-04-20 |
노파르티스 아게 |
상피 나트륨 채널 차단제로서의 피라진 유도체
|
|
ES2396023T3
(es)
|
2009-01-29 |
2013-02-18 |
Novartis Ag |
Bencimidazoles sustituidos para el tratamiento de astrocitomas
|
|
US8481731B2
(en)
*
|
2009-06-24 |
2013-07-09 |
Boehringer Ingelheim International Gmbh |
Compounds, pharmaceutical composition and methods relating thereto
|
|
US8293729B2
(en)
*
|
2009-06-24 |
2012-10-23 |
Boehringer Ingelheim International Gmbh |
Compounds, pharmaceutical composition and methods relating thereto
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
BR112012003262A8
(pt)
|
2009-08-12 |
2016-05-17 |
Novartis Ag |
compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
|
|
UA111579C2
(uk)
|
2009-08-17 |
2016-05-25 |
Інтеллікіне Ллк |
ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
|
|
IN2012DN01453A
(cg-RX-API-DMAC7.html)
|
2009-08-20 |
2015-06-05 |
Novartis Ag |
|
|
AU2010310449A1
(en)
|
2009-10-22 |
2012-05-03 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
UY33597A
(es)
|
2010-09-09 |
2012-04-30 |
Irm Llc |
Compuestos y composiciones como inhibidores de la trk
|
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
|
CA2817847C
(en)
*
|
2010-11-12 |
2018-02-13 |
The Johns Hopkins University |
Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease
|
|
US10309974B2
(en)
|
2010-11-12 |
2019-06-04 |
Cedars-Sinai Medical Center |
Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease
|
|
WO2012107500A1
(en)
|
2011-02-10 |
2012-08-16 |
Novartis Ag |
[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
|
BR112013021638A2
(pt)
|
2011-02-25 |
2016-08-02 |
Irm Llc |
"compostos inibidores de trk, seu uso e composições que os compreendem"
|
|
US8883819B2
(en)
|
2011-09-01 |
2014-11-11 |
Irm Llc |
Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
|
|
UY34329A
(es)
|
2011-09-15 |
2013-04-30 |
Novartis Ag |
Compuestos de triazolopiridina
|
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
JP6165733B2
(ja)
|
2011-09-16 |
2017-07-19 |
ノバルティス アーゲー |
N−置換ヘテロシクリルカルボキサミド類
|
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
|
CN103946221B
(zh)
|
2011-09-16 |
2016-08-03 |
诺华股份有限公司 |
用于治疗囊性纤维化的杂环化合物
|
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
US9174994B2
(en)
|
2011-11-23 |
2015-11-03 |
Intellikine, Llc |
Enhanced treatment regimens using mTor inhibitors
|
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
|
MX371119B
(es)
|
2012-04-03 |
2020-01-17 |
Novartis Ag |
Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
|
|
US9433680B2
(en)
|
2013-01-31 |
2016-09-06 |
Merz Pharmaceuticals, Llc |
Topical compositions and methods for making and using same
|
|
US8778365B1
(en)
|
2013-01-31 |
2014-07-15 |
Merz Pharmaceuticals, Llc |
Topical compositions and methods for making and using same
|
|
US9446131B2
(en)
|
2013-01-31 |
2016-09-20 |
Merz Pharmaceuticals, Llc |
Topical compositions and methods for making and using same
|
|
US9452173B2
(en)
|
2013-01-31 |
2016-09-27 |
Merz Pharmaceuticals, Llc |
Topical compositions and methods for making and using same
|
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
|
HK1219421A1
(zh)
|
2013-03-15 |
2017-04-07 |
因特利凯有限责任公司 |
激酶抑制剂的组合及其用途
|
|
TW201605450A
(zh)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Mdm2抑制劑與BRAF抑制劑之組合及其用途
|
|
KR20160145780A
(ko)
|
2014-04-24 |
2016-12-20 |
노파르티스 아게 |
포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
|
|
AU2014391610B2
(en)
|
2014-04-24 |
2018-01-25 |
Novartis Ag |
Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
CA2945212A1
(en)
|
2014-04-24 |
2015-10-29 |
Novartis Ag |
Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
|
US10195208B2
(en)
|
2014-07-31 |
2019-02-05 |
Novartis Ag |
Combination therapy
|
|
EP3268085A4
(en)
|
2015-03-13 |
2018-10-31 |
The Board of Trustees of The Leland Stanford Junior University |
Ltb4 inhibition to prevent and treat human lymphedema
|
|
EP3311176A4
(en)
|
2015-06-18 |
2019-03-13 |
Cedars-Sinai Medical Center |
ROLE OF CITRULLINATION IN THE DIAGNOSIS OF ILLNESSES
|
|
CN107286101B
(zh)
*
|
2017-07-27 |
2020-04-21 |
云南大学 |
1-芳醛肟尿嘧啶及其制备方法
|
|
US20200383960A1
(en)
|
2019-06-10 |
2020-12-10 |
Novartis Ag |
Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis
|
|
KR20220052934A
(ko)
|
2019-08-28 |
2022-04-28 |
노파르티스 아게 |
치환 1,3-페닐 헤테로아릴 유도체 및 질환 치료에서의 이의 용도
|
|
TW202140550A
(zh)
|
2020-01-29 |
2021-11-01 |
瑞士商諾華公司 |
使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
|
|
US11116737B1
(en)
|
2020-04-10 |
2021-09-14 |
University Of Georgia Research Foundation, Inc. |
Methods of using probenecid for treatment of coronavirus infections
|
|
CN117558997B
(zh)
*
|
2024-01-11 |
2024-04-02 |
河南鑫泉能源科技有限公司 |
一种锂离子电池电解液及其制备方法与电池
|